1.Ji Yeung Oh, Chun June Lee. Comparative study of an aprepitant regimen with an ondansetron regimen, for efficacy in gynecological cancer patients with chemotherapy. Korean Journal of Obstetrics and Gynecology. 2009. 5:538–44.
2.Richardson JL., Mark G., Levine A. Theinfluence of symptoms of vomiting with cytotoxic chemotherapy. hournal of Clinical Oncology. 1988. 6(11):1746–52.
3.Morran C., Smith DC., Anderson DA, et al. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. BJM. 1979. 1:1323–9.
4.Harmon J., John HW. Control of cancer chemotherapy induced nausea and vomiting. Cancer. 1984. 54:2642–50.
5.Hmosley HD., Gainey JM., Jobson VW, et al. Double blind placebo controlled study of metoclopramide. N Engl J Med. 1982. 307:250–9.
6.Bateman DN., Rawlins MD., Simpson JM. Extrapyramidal rreactions with metocloprimide. BKM. 1982. 291:930–9.
7.Roila F., Donati D., Tamberi S., Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002. 10:88–95.
Article
8.Hesketh PJ., Van Belle S., Aapro M., Tattersall FD., Naylor RJ., Hargreaves R, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003. 39:1074–80.
Article
9.Hesketh PJ., Grunberg SM., Gralla RJ., Warr DG., Roila F., de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebocontrolled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003. 21:4112–9.
Article
10.Poli-Bigelli S., Rodrigues-Pereira J., Carides AD., Julie Ma G., Eldridge K., Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo- controlled trial in Latin America. Cancer. 2003. 97:3090–8.
11.Leibundgut U., Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet. 1987. 1:1198.
Article
12.Ballatori E., Roila F., De Angelis V., Ciccarese G., Palladino MA., Tonato M, et al. Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer. Support Care Cancer. 1997. 5:269–73.
13.Gebbia V., Cannata G., Testa A., Curto G., Valenza R., Cipolla C, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer. 1994. 74:1945–52.
14.Ballatori E., Roila F., De Angelis V., Ciccarese G., Palladino MA., Tonato M, et al. Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer. Support Care Cancer. 1997. 5:269–73.
15.Gralla RJ. Metoclopramide. A review of antiemetic trials. Drugs. 1983. 25(Suppl 1):63–73.
16.Gralla RJ., Osoba D., Kris MG., Kirkbride P., Hesketh PJ., Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 2002. 17:2971–94.
17.Roila F., Tonato M., Cognetti F., Cortesi E., Favalli G., Marangolo M, et al. Prevention of cisplatininduced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991. 9:675–8.
Article
18.Min SH., Kim DS., Cho YS., Nam SW., Kim IS., Lim JW, et al. A Phase III Study of Ondansetron & Metoclopramide in the Management of Cisplatin-Induced Emesis. Korean Journal of Obstetrics & Gynecology. 1994. 37:542–51.
19.Kim YB., Kim JW., Seo DG., Lee CM., Park NH., Song YS, et al. A Randomized Comparison of Tropisetron versus Ondansetron in the Control of Nausea and Vomiting in Gynecologic Cancer Patients Undergone Cisplatin-Based Chemotherapy. Korean Journal of Obstetrics & Gynecology. 1998. 41:2544–50.